Table 1 Demographics and clinical features of the study populations
From: Platelet-activating factor acetylhydrolase in primary antiphospholipid syndrome
CTR | IT | PAPS | |
|---|---|---|---|
Participants (no.) | 23 | 17 | 27 |
Female/male | 13/7 | 11/6 | 18/9 |
Age (range) | 42 (19–55) | 40 (30–58) | 38 (27–53) |
Lupus anticoagulant | 0 | 0 | 28 |
IgGaCL (GPL) | 3 (1.5–6.0) | 3.2 (1.4–6.8) | 122 (24–573) |
IgGβ2GPI (IU) | 1 (0.78–3.4) | 2 (0.8–4.8) | 183 (31–226) |
β2GPI-oxLDL (IU) | 1.6 (1.0–9.0) | 1.6 (0.5–6.5) | 1.4 (0.8–1.8) |
PAF-AH (nmol/ml/min) | 46 (22–88) | 43 (30–79) | 39 (1.8–80)a |
FVL | 0 | 12 | 2 |
PT 20210 | 1 | 2 | 1 |
PC deficiency | 0 | 3 | 0 |
IS | 0 | 2 | 7 |
MI | 0 | 0 | 1 |
DVT | 0 | 11 | 14 |
PE | 0 | 4 | 5 |
Smoking | 2 | 2 | 4 |
Diabetes | 0 | 0 | 0 |
Obesity | 0 | 0 | 0 |
Aspirin (75 mg) | 0 | 3 | 1 |
Warfarin | 0 | 14 | 26 |